Hologic launches initiative for affordable access to diagnostic tests

26 July 2018 (Last Updated July 26th, 2018 12:22)

Hologic has launched a new initiative to enhance access to its molecular tests intended for the diagnosis of certain infectious diseases in approximately 50 countries, including African and Southeast Asian regions.

Hologic has launched a new initiative to enhance access to its molecular tests intended for the diagnosis of certain infectious diseases in approximately 50 countries, including African and Southeast Asian regions.

The new Hologic Global Access Initiative will be carried out in alliance with the Clinton Health Access Initiative (CHAI) and the UK-backed MedAccess.

It focuses on offering affordable testing for human immunodeficiency virus (HIV), hepatitis B and C (HBV and HCV) and human papillomavirus (HPV) infections.

"Hologic said that the programme optimises overall lab systems efficiency, minimises instrument downtime and reduces stockouts and waste, thereby supporting Integrated Diagnostics Consortium objectives."

Set to be rolled out in August this year, the initiative features single, all-inclusive pricing without any upfront costs or capital expenditure.

The programme will aim to improve access to the company’s automated molecular testing platform called Panther system, which is suitable for centralised as well as decentralised labs.

Panther system can deliver up to 320 results in eight hours and can be run with Aptima HIV-1, HCV and Quant assays. The Aptima HPV assay to detect 14 high-risk HPV types related to cervical cancer can also be run on this platform.

Hologic Diagnostic Solutions division president Tom West said: “Through this initiative in partnership with the global public health community, we’re determined to make an even greater impact in countries with limited resources and help reduce the burden of global infectious diseases, especially HIV.”

The initiative is said to be in line with UNAIDS’ 90-90-90 goal, which aims to have 90% of people living with HIV diagnosed by 2020, 90% diagnosed patients will get sustained antiretroviral treatment, and 90% of those on antiretroviral therapy will have viral suppression.

Hologic added that the programme optimises overall lab systems efficiency, minimises instrument downtime and reduces stockouts and waste, thereby supporting Integrated Diagnostics Consortium objectives.